Cell Therapy Processing Market Report 2026

The cell therapy processing market size has grown rapidly in recent years. It will grow from $5.18 billion in 2025 to $5.92 billion in 2026 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to increasing clinical trials for cell therapies, expansion of biopharmaceutical manufacturing capacity, availability of specialized processing facilities, growing expertise in gmp compliance, rising investment in advanced therapeutics.

The cell therapy processing market size is expected to see rapid growth in the next few years. It will grow to $9.93 billion in 2030 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to increasing commercialization of gene and cell therapies, rising demand for contract manufacturing services, expansion of decentralized manufacturing models, growing adoption of digital quality management systems, increasing regulatory approvals for cell-based therapies. Major trends in the forecast period include increasing adoption of gmp-compliant processing platforms, rising demand for scalable cell therapy manufacturing, growing integration of workflow automation software, expansion of contract processing services, enhanced focus on sterility and quality assurance.

The rising number of cell therapy research activities is expected to drive the growth of the cell therapy processing market going forward. Cell therapy involves the manufacturing of therapeutic products derived from living cells to treat or manage various diseases, including cancers, autoimmune disorders, and genetic conditions. The demand for cell-based therapies is increasing due to the growing need for scalable and consistent manufacturing platforms capable of supporting high cell densities without compromising product quality. Cell therapy processing supports research by enabling standardized preparation, quality control, and scalable production of high-quality cells, ensuring reliable and reproducible outcomes for both experimental and clinical studies. For instance, in December 2024, the International Federation of Pharmaceutical Manufacturers and Associations, a Switzerland-based non-profit organization, reported that six first-in-class cell and gene therapies were introduced in 2023, representing a 50% increase compared with the three introduced in 2022. Therefore, the rising number of cell therapy research activities is driving the growth of the cell therapy processing market.

Major companies operating in the cell therapy processing market are focusing on developing advanced solutions, such as integrated bioreactor-centrifuge systems, to streamline manufacturing workflows and enhance the consistency, scalability, and sterility of cell-based therapies. An integrated bioreactor-centrifuge system is a single, unified device that combines cell incubation and centrifugal separation within a closed unit, enabling continuous, automated cell processing without intermediate transfers. For instance, in March 2025, Limula SA, a Switzerland-based cell and gene therapy (CGT) company, launched LimONE, an automated, closed-system platform for cell therapy manufacturing. This innovative system integrates hardware, single-use consumables, and protocol-driven software to consolidate complex cell processing steps, including incubation, centrifugation, and reagent handling, into one compact unit, enabling consistent, scalable production of therapies such as CAR-T and gene-edited stem cells from research through GMP-compliant manufacturing without the need for complex technology transfers.

In May 2025, AstraZeneca PLC, a UK-based pharmaceutical company, acquired ESO Biotech for $1 billion. Through this acquisition, AstraZeneca aims to expand its rare disease portfolio by integrating ESO Biotech’s gene-editing technology to strengthen its genomic medicine capabilities. ESO Biotech is a Belgium-based company that develops next-generation gene-editing therapies for rare diseases.

Major companies operating in the cell therapy processing market are Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Novartis AG, Gilead Sciences Inc., Danaher Corporation, Lonza Group AG, Anterogen Co. Ltd., Terumo Corporation, Sartorius AG, Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec GmbH, AGC Biologics S.p.A., MaxCyte Inc., Cellares Corporation, Cellectis S.A., JW Cayman Therapeutics Company Limited, Cell Therapies Pty Ltd., InGeneron Inc., WuXi Advanced Therapies, Catalent Inc.

North America was the largest region in the cell therapy processing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy processing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell therapy processing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the cell therapy processing market by increasing costs of imported processing systems, sterile consumables, automation software, and quality control equipment used in gmp-compliant environments. Biopharmaceutical manufacturers in North America and Europe are most affected due to reliance on specialized imported components, while asia-pacific faces higher setup costs for new processing facilities. These tariffs are increasing production costs and extending facility commissioning timelines. However, they are also driving localized manufacturing, regional service provider growth, and increased investment in domestic cell therapy processing capabilities.

The cell therapy processing market research report is one of a series of new reports that provides cell therapy processing market statistics, including cell therapy processing industry global market size, regional shares, competitors with a cell therapy processing market share, detailed cell therapy processing market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy processing industry. This cell therapy processing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell therapy processing refers to the series of steps involved in collecting, modifying, and preparing living cells for therapeutic use. It includes cell isolation, activation, genetic modification, expansion, and formulation under strict sterile and quality-controlled conditions. These processes are performed in compliance with good manufacturing practices (GMP) to ensure safety, purity, and potency.

The primary offerings of cell therapy processing include products, services, and software. Products include the physical tools, reagents, cell lines, and advanced instruments needed for handling, cultivating, and preparing cells. These are applied in cardiovascular therapies, bone repair, neurological disorders, skeletal muscle repair, cancer, and others, serving several end users, including research institutes, biopharmaceutical companies, contract research organizations, and others.

The cell therapy processing market consists of revenues earned by entities by providing services such as cell isolation, enrichment services, cell expansion, cryopreservation, and cell characterization. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell therapy processing market also includes sales of cell culture bioreactors, cell counting analyzer, flow cytometers, and viral vector production systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.